# Lang Sheng Investment

> Lang Sheng Investment is a VC fund in Shanghai backing Health Care and Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 14
- Last investment: Mar 2023
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/langshenginvestment/
- Website: http://www.cnlsi.com/en/

Lang Sheng Investment is a leading life science and big data investment firm in China committed to helping exceptional entrepreneurs build the next generation of great healthcare and big data companies.They invest across the healthcare and big data sectors with an emphasis on the venture stages of company development. With close to RMB600 millionunder management and the headquarters in Shanghai, Lang Sheng has built a team with strong investment expertise. Since the firm’s founding in 2010, they have invested in 23 companies in the life science and big data companies in China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 29% |
| Biotechnology | 4 | 29% |
| Medical | 3 | 21% |
| Software | 3 | 21% |
| Pharmaceutical | 3 | 21% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 36% |
| Series B | 3 | 21% |
| Series C | 2 | 14% |
| Seed | 1 | 7% |
| Angel | 1 | 7% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Svision | Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. | $43.1M | Series C | Mar 09, 2023 |  |
| CotheraBio | CotheraBio develops innovative cancer therapies with a focus on translational oncology. It has developed its proprietary i-CR® technology platform, which is a powerful method for providing individualized drug screening and new drug development. The platform combines a high content screening system with the conditional reprogramming of primarycultured tumor cells, which enables the efficient and undifferentiated expansion of primary patient-derived tumor cells in vitro, while also preserving the tumor’s heterogeneity. |  | Venture - Series Unknown | Jan 02, 2021 |  |
| Suochen Information Technology | Suochen Information is a system software and hardware R&D and SAAS service provider, providing customers with product life cycle collaborative development system software and hardware, SAAS services. Products and services cover research and development frontier engineering, digital design and intelligent manufacturing. Customers are widelydistributed in heavy machinery, ground transportation, electronics, construction, aviation, aerospace, weapons, ships, optoelectronics, power equipment and other industries. |  | Series B | Feb 26, 2019 |  |
| Moviebook | Moviebook is a Chinese startup in the video recognition and online video technology areas. It is committed to developing video interaction platform of revolutionary significance and high commercial value. Driven by technology, its innovation is embracing the online video industry, and is opening a creative development path.Moviebook is based inBeijing, China. | $198.4M | Series D | Aug 07, 2018 |  |
| Svision | Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. | $3.8M | Series A | Jun 29, 2018 |  |
| Abmart | Abmart specializes in antibody customization and antibody-related services. | $2.8M | Series B | Jun 12, 2018 |  |
| ImmuneOnco Biopharma | ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells. |  | Series A | Apr 11, 2018 |  |
| CargoGM | Logistic |  | Seed | Mar 05, 2018 |  |
| CapitalBio Technology | CapitalBio Technology is an industry-leading life science company that develops and commercializes total health-care solutions. Their company provides a comprehensive portfolio of top-quality products to a diverse customer base ranging from biomedical researchers to healthcare professionals. Their products include an innovative and broad spectrumof microarray and microfluidic chips and related instruments, software and databases, reagents and consumables for basic and translational research, drug development, clinical diagnostics, biosafety and food safety, and molecular breeding.As a core subsidiary of CapitalBio Corporation and the Biological Chip Beijing National Engineering Research Center, CapitalBio Technology was registered in August 2012 and is headquartered in Economic-Technological Development Area in Beijing. CapitalBio Technology is a leading life science company that develops and commercializes total health-care solutions. With more than 35,000 square meters of office space, CapitalBio Technology employs more than 500 employees; 86 percent of these employees have at least Bachelor-level degrees, 14 of which are doctors or post-doctorates. | $2.8M | Series B | Dec 18, 2017 |  |
| AutocloudPro | The "CarTongyun" intelligent maintenance platform provides accurate information through its comprehensive database. The system covers nearly 2,500 vehicles, including imported, autonomous, joint venture vehicles, and nearly 150,000 vehicle types. At present, more than 80% of the models required by the domestic auto repair industry, inwhich the part data of each model has covered all the parts damaged by daily collisions, covering more than 95% of the total. Quickly locate and repair the required parts information, and at the same time, it can provide data support for user procurement, loss determination, and out-of-factory rescue scenarios according to the related parameters such as coding query and original price. | $17M | Series A | Jul 28, 2017 |  |

10 of 14 investments shown.

## Co-investors
- [Flyfot Ventures](https://shizune.co/investors/profile/flyfot-ventures) — VC Fund, 2 deals together
- [Lapam Capital](https://shizune.co/investors/profile/lapam-capital) — VC Fund, 2 deals together
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 2 deals together
- [ABC Capital](https://shizune.co/investors/profile/abccapital) — VC Fund, 1 deal together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 1 deal together
- [Aier Eye Hospital Group](https://shizune.co/investors/profile/aier-eye-hospital-group) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [Global Founders Capital](https://shizune.co/investors/profile/global-founders-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Recruiting Investors in China](https://shizune.co/investors/recruiting-investors-china)
- [Recruiting VC Funds in China](https://shizune.co/investors/recruiting-vc-funds-china)

## FAQ

### What does Lang Sheng Investment invest in?

Lang Sheng Investment invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lang Sheng Investment last invest?

The most recent investment recorded for Lang Sheng Investment closed in Mar 2023. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co